Paper · 37364231
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.
Heipertz AE and 25 others. JCO Precis Oncol, 2023. Cited by 33 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. Papers, record 37364231. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37364231
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma | Major topic |
| Animals | |
| Humans | |
| Child | |
| Adolescent | |
| Proto-Oncogene Proteins B-raf | |
| Precision Medicine | |
| Neoplasm Recurrence, Local | |
| Receptor Protein-Tyrosine Kinases | |
| TOR Serine-Threonine Kinases | |
| Mitogen-Activated Protein Kinase Kinases | |
| Mammals |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 37,499,193 | Erratum: Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. | https://conductscience.org/library/papers/37499193 |
Source PubMed
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,620,518 | High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors. | Res Sq | 2026 | https://conductscience.org/library/papers/42620518 | PubMed |
| 42,619,885 | High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors. | medRxiv | 2026 | https://conductscience.org/library/papers/42619885 | PubMed |
| 42,509,573 | Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience. | Genome Med | 2026 | https://conductscience.org/library/papers/42509573 | PubMed |
| 42,393,274 | Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42393274 | PubMed |
| 41,963,440 | Ependymoma group-specific blood-brain barrier differences uncovered by a multi-omics approach. | Sci Rep | 2026 | https://conductscience.org/library/papers/41963440 | PubMed |
| 41,520,034 | Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41520034 | PubMed |
| 41,417,259 | Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors. | Cancer Res | 2026 | https://conductscience.org/library/papers/41417259 | PubMed |
| 41,210,226 | Targeted therapy in patients with genetic tumor syndromes. | Med Genet | 2025 | https://conductscience.org/library/papers/41210226 | PubMed |
| 41,097,748 | Striking at Survivin: YM-155 Inhibits High-Risk Neuroblastoma Growth and Enhances Chemosensitivity. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097748 | PubMed |
| 41,076,459 | Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM. | Acta Neuropathol | 2025 | https://conductscience.org/library/papers/41076459 | PubMed |
1 to 10 of 25
See all 25 cited byGenes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALK | 238 | PubTator's text mining | https://conductscience.org/library/genes/238 | NCBI Gene |
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| MAP2K7 | 5,609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MTOR | 2,475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37364231
GET https://conductscience.org/api/papers/v1/37364231/authors?page=2